Although multiple studies in NSCLC have failed to show benefit of HER2 directed treatment, these studies were performed in patients with HER2 expression, irrespective of the co-occurrence of an activating EGFR mutation and tested the hypothesis of HER2 being an oncogenic driver in NSCLC.16–22. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.